PolyPeptide Group AG (LTS:0AAJ) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AAJ PolyPeptide Group AG LTS:0AAJ
60 GF Score
Price CHF43.82
GF Value CHF31.32
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PolyPeptide Group AG FFO per Share?

FFO per Share only applies to REITs.

LTS:0AAJ
60GF Score
PolyPeptide Group AG LTS:0AAJ
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PolyPeptide Group AG (LTS:0AAJ) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF43.82 is trading 39.9% above its estimated GF Value™ of CHF31.32. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for LTS:0AAJ:

  • FFO per Share:
  • GF Value™: CHF31.32 vs. price of CHF43.82 (39.9% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the LTS:0AAJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
60GF Score

Get the complete analysis for LTS:0AAJ

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF43.82
Price
CHF31.32
GF Value